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Background: Growth rate In children is reported to have seasonal variability. There are fewer published data
regarding seasonal variability while on growth hormone (GH) therapy, and none analyzing growth rate with respect
to number of daylight hours.
Methods: We analyzed 11,587 3-month intervals in 2277 prepubertal children (boys ages 3–14 years, girls ages 3–
12 years) with idiopathic GH deficiency from the National Cooperative Growth Study (NCGS) database. All were
naive to recombinant human GH (rhGH) therapy. Data were submitted from 31 US study centers. Seasonal variation
in height velocity (HV) was assumed to be associated with the average number of daylight hours during the
interval of time over which HV was computed. Number of daylight hours was determined from the date of the
measurement and the latitude of the study center. Other independent variables evaluated included: height
standard deviation score (SDS) at the beginning of the interval, chronologic age at the beginning of the interval,
time from the start of rhGH treatment to the middle of the interval, month of the year, body mass index SDS at the
beginning of the interval, rhGH dose/kg, mother’s height SDS, father’s height SDS, and log base 10 of the
maximum stimulated GH concentration.
Results: All variables examined, except month of the year, correlated significantly with interval HV. There was
significant “seasonal” variability at all latitudes, with summer annualized HV being greater than winter HV. This
difference was greatest in the first year of therapy (0.146 cm/yr/daylight hour; P < 0.0001) but persisted in
subsequent years (0.121 cm/yr/daylight hr; P < 0.0001). The difference increased with distance from the equator.
Growth rate over the year was not different among the latitudes reflected in this North American study.
Conclusions: There is “seasonal” variation in growth of children on rhGH therapy that correlates with number of
daylight hours. The effect is modest and is greatest in the first year of therapy. Annual growth rate appears to be
equal in children among latitudes covered by the US consistent with exposure to an equal number of daylight
hours over the year. The physiologic mechanism behind this seasonal variation is not yet understood.
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Growth rate in children varies during the calendar year,
with a faster rate of growth during the spring/summer
than in the winter [1,2]. “Seasons” per se are not fixed
throughout the world, as definitions vary as to whether
they are meteorologically defined, culturally defined by
holidays, or socially defined by the school year. Never-
theless, the most constant definitions focus on warmth
and sunlight with the most reproducable mathematical
variable for seasonality being the number of daylight
hours. “Seasonal” variation has been evaluated to a lesser
extent in children on growth hormone (GH) therapy
[3-5] and has not specifically been evaluated with
respect to number of daylight hours. As the National
Cooperative Growth Study (NCGS) database now con-
tains 220,000 patient-years of growth data on children
receiving recombinant human growth hormone (rhGH)
therapy, we asked the following questions: 1) Does ex-
ogenous rhGH obscure “seasonal” variability in height
velocity (HV) in prepubertal children with isolated
growth hormone deficiency (IGHD) in North America?
2) Is the magnitude of the “seasonal” difference in HV
enough to influence clinical decision making regarding
assessment of efficacy of a short trial of rhGH therapy?
3) Are there differences in annual HV in treated children
with IGHD living at northern and southern latitudes in
the United States?
Methods
The NCGS database was initiated in December 1985 to
collect data in children treated with rhGH for evaluation
of safety and efficacy. Anonymous data were entered by
clinical investigators in the US including date of birth,
sex, height, weight, etiology of short stature, peak serum
GH response to stimulation testing, Tanner pubertal
stages, parental heights, and GH dose for patients trea-
ted with Genentech’s rhGH products. The database
reflects 220,000 rhGH treatment years.
Patients
Analysis was performed using 2277 patients with IGHD
(peak GH response to stimulation testing <10 ng/mL)
chosen from 31 US clinical study centers in the NCGS
database spanning the range of latitudes in the United
States. Patients were GH naive, boys were restricted to
ages 3 to 14 years and girls to ages 3 to 12 years, and
prepubertal during the time intervals for which HV was
assessed. Duration of treatment range was 3 months to
10 years.
Analysis of seasonal variation in HV
Seasonal variation in HV was assumed to be associated
with the average number of daylight hours during the
interval of time over which HV was computed. Thenumber of daylight hours depends both on date and lati-
tude. Latitude was assumed to be that of the study site.
HV was assessed for 11,587 3-month intervals for these
2277 patients. The average number of daylight hours
was computed for each interval. Other independent vari-
ables included: height standard deviation score (SDS) at
the beginning of the interval, chronologic age at the be-
ginning of the interval, time from the start of rhGH
treatment to the middle of the interval, month of the
year, body mass index (BMI) SDS at the beginning of the
interval, rhGH dose/kg at the beginning of the interval,
mother’s height SDS, father’s height SDS, and log base
10 of the maximum stimulated GH concentration.
In NCGS, there was no required frequency for the
measurement of heights. For each patient, 3-month HV
was computed for each time interval between height
measurements for which the interval length was between
2 and 4 months, i.e., between approximately 60 days and
120 days. Thus, if the time interval between two succes-
sive heights for a patient was greater than 120 days, then
no HV for that time interval was used. For example, if
the time from baseline for measurement of heights for a
patient was 30, 89, and 180 days, then HVs were com-
puted for the interval from baseline to day 89 and for
the interval from day 89 to day 180. In order to distin-
guish the seasonal effect from the effect of daylight
hours, the month of the year was added to the regres-
sion model for the 3-month HVs during the first year of
therapy. Specifically, the month of the year for the mid-
point of the time interval for each HV was used. (For ex-
ample, if a “3-month” time interval started on April 3
and ended on July 10, then the mid-point would be May
22, so the month for the mid-point would be May.)
Because multiple measurements were used for each
patient, the SAS mixed models procedure was used to
perform the analysis. The analysis was performed using
the June 2011 version of the NCGS database.Results
Results are summarized in Tables 1 and 2. Each of the
independent variables evaluated, except month of the
year, contributed significantly to the prediction of the 3-
month interval HV during the first year. The regression
coefficient for the average number of daylight hours was
0.146 cm/yr per daylight hour in year 1 of rhGH treat-
ment, and 0.121 cm/yr per daylight hour in subsequent
treatment years (P < 0.0001). The overall average was
0.133 cm/yr per hour of daylight (P < 0.0001). In the
multiple regression analysis there was no statistical rela-
tionship between month of the year and the 3-month
interval growth rate (P = 0.65), while the average number
of daylight hours during the interval remained highly
statistically significant.
Table 1 3-Month height velocity during the first year of treatment and regression coefficients
(2090 Patients, 5033 HVs)
Mean (SD) Regression coefficent P value
3-month HV during 1st year (cm/yr) 9.7 (3.7)
Daylight hours 11.9 (1.7) 0.146 <0.0001
Age (yr) at start of 3-month interval 9.0 (2.8) −0.22 <0.0001
Height SDS at start of 3-month interval −2.2 (0.8) 0.28 <0.0001
BMI SDS at start of 3-month interval −0.4 (1.1) 0.52 <0.0001
Mother’s height SDS −0.6 (1.1) 0.19 <0.0001
Father’s height SDS −0.4 (1.1) 0.10 0.0340
Maximum stimulated GH (ng/mL) 6.1 (2.4) −2.1* <0.0001
GH Dose (mg/kg/wk) at start of 3-month interval 0.30 (0.05) 7.9 <0.0001
Time from GH start to midinterval for HV (yr) 0.4 (0.3) −3.57 <0.0001
*Using log base 10 of maximum stimulated GH response.
GH, growth hormone; HV, height velocity; SD, standard deviation; SDS, standard deviation score.
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annualized HV from some of the clinical sites are pro-
vided in Figure 1.
In Seattle, Washington, at 48° latitude, the average
number of daylight hours during the 3 months of the
year with the shortest days (roughly November 6 to Feb-
ruary 5) is 8.6 hours and during the 3 months with the
longest days (roughly May 6 to August 6) is 15.4 hours;
the mean difference in annualized HV between these 2
periods during the first year of treatment is 0.99 cm/yr
(6.8 hr × 0.146 cm/yr/daylight hour).
In Miami, Florida, at 26° latitude, the average number
of daylight hours during the 3 months of the year with
the shortest days is 10.6 hours, compared with 13.5 hours
during the longest days; the mean difference in the
annualized HV in the first year is 0.42 cm/yr in the first
year.
In Anchorage, Alaska, at 61° latitude, average number
of daylight hours during the 3 months of the year with
the shortest days is 6.1 hours, compared with 17.9 hoursTable 2 3-Month height velocity after the first year of treatm
(1292 Patients, 6356 HVs)
Mean (S
3-month HV after 1st year (cm/yr) 7.2 (2.9
Daylight hours 11.9 (1.7
Age (yr) at start of 3-month interval 9.2 (2.1
Height SDS at start of 3-month interval −1.4 (1.
BMI SDS at start of 3-month interval −0.1 (1.
Mother’s height SDS −0.6 (1.
Father’s height SDS −0.4 (1.
Maximum stimulated GH (ng/mL) 6.1 (2.4
GH dose (mg/kg/wk) at start of 3-month interval 0.32 (0.0
Time from GH start to midinterval for HV (yr) 2.8 (1.5
*Using log base 10 of maximum stimulated GH response.
GH, growth hormone; HV, height velocity; SD, standard deviation; SDS, standard deduring the longest days; the difference in the annualized
HV between winter and summer is 1.7 cm/yr in the first
year.
In Honolulu, Hawaii, at 21° latitude, the site closest to
the equator, the difference between the daylight hours
between the 3 months of winter with the shortest days
(10.9) and those of summer with the longest days (13.1)
was the smallest among the illustrated sites, and the dif-
ference in annualized HV between winter and summer
the smallest as well, 0.32 cm/year.
There was no effect of latitude on HV measured over
the entire first year (P = 0.40). BMI SDS was unrelated to
the number of daylight hours (P = 0.28).
The role of peak stimulated GH concentration on the
magnitude of the effect of daylight hours on 3-month
HVs during the first year of GH therapy was analyzed.
Of 2277 patients, only 342 had maximum stimulated
GH ≤ 3 ng/mL (includes 5033 3-month HV intervals). In
this analysis, the effect of peak GH was slightly statisti-
cally significant (P = 0.027). The regression coefficientent and regression coefficients













Winter 10.9 hr 
Summer 13.1 hr 
ΔHV 0.32 cm/yr
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Winter 8.6 hr 
Summer 15.4 hr 
ΔHV 0.99 cm/yr
Anchorage 610
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Winter 10.6 hr 
Summer 13.5 hr 
ΔHV 0.42 cm/yr
Figure 1 Effect of daylight hours on height velocity (HV).
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GH ≤ 3 ng/mL was 0.183 and was 0.140 for those with a
response > 3 ng/mL but less than 10.Discussion
Seasonal variation in growth has been reported for
normally growing children by several authors, most
reporting peak growth during the summer months in
the Northern Hemisphere [1-3]. Ikeda and Watanabe
did not identify seasonal variation in growth of 1000
Japanese school children ages 6–11 years studied be-
tween 1983 and 1984 [6]. They attributed this to the use
of modern home-heating systems. Lee studied 27 boys
and girls in Oakland, California, and observed persistent
seasonal variability despite living in a climate that had
little variation in temperature and humidity throughout
the year, suggesting that temperature was not an import-
ant factor [2].
Number of daylight hours is thought to play a role in
variation of seasonal growth rates, although the mechan-
ism is not understood. Blind children have been reported
to have limited variation in growth rate throughout the
year [7]. Rudolf et al. performed GH stimulation testing
and integrated 24-hour GH profiles in 84 normally
growing children in 2 consecutive seasons and identified
no differences in GH or insulin-like growth factor 1
(IGF-1) levels to account for the observed variation in
growth rate [5]. These authors also evaluated growth in
52 GH-deficient children and identified seasonal variabi-
tity in growth even on GH therapy. Growth rate gener-
ally peaked in summer, and was lowest in the Israeliautumn. They concluded that the effect of daylight
hours appears to not be mediated through GH secretion.
In an early NCGS summary report, Tiwary noted sea-
sonal variation in GH-treated patients with idiopathic
short stature, IGHD, and Turner syndrome [3]. In our
study, 3-month HV data have been analyzed in a large
number children diagnosed with IGHD children who
were initially naive to GH therapy. Seasonal variability in
HV during rhGH therapy was associated with number of
daylight hours and was most apparent at latitudes far-
thest from the equator. The effect of daylight hours
appears greatest in the first year but persists throughout
subsequent years of therapy. The effect is modest and is
likely to affect clinical assessment of short-term growth
rate (3 to 4 months) only in latitudes far from the
equator, particularly if there are additional contributing
factors, such as intercurrent illness or intermittent com-
pliance. Effect of daylight hours is slightly greater in chil-
dren with peak stimulated GH response ≤ 3 ng/mL,
however, the significance of this obervation is unclear
due to small sample size.
Interestingly, annual HV, or total growth over the year,
does not differ according to latitude, consistent with an
equal total annual daylight hour exposure. Growth appears
to speed up during times of greatest daylight exposure and
slow down during periods of darkness, but overall has a
consistent yearly “program,” possibly at the level of the
growth plate. In a recent summary paper regarding evolu-
tion of the eye, Lamb describes the primitive eye, from
which the current mammalian eye evolved 600 million
years ago, as a light-sensitive organ whose function was
that of maintaining circadian and seasonal rhythms [8].
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the pineal gland and regulates melatonin secretion affect-
ing circadian and seasonal rhythms [9,10]. Pinealectomy
eliminates daylight-entrained circadian patterns [11]. Mela-
tonin has been implicated in gonadotropin regulation and
more recently glucose metabolism/insulin sensitivity [12-
15]. Recently, GH response to GH-releasing hormone and
spontaneous GH secretion in sheep were demonstrated to
be greater during a long versus short photoperiod, and GH
amplitude was reduced by melatonin administration [16].
Effects of daylight hours on energy metabolism, other sig-
naling at the level of the growth plate, or even GH secre-
tion that were not identified in previous studies due to
small numbers of patients evaluated may play a role. In
plants, DNA methylation is involved in the photoregula-
tion of flowering [17]. Melatonin may also induce epigen-
etic changes in DNA expression [18]. The observation that
seasonal variation persists with continuous exogenous GH
therapy, suggests that GH, if involved, is one of several
factors.
In our analysis, BMI SDS at the start of each interval
was associated with the HV of that interval. It is possible
that weight gain during less active winter months in
northern climates facilitates increased growth rate in
summer. In the southern US, children’s activity level and
weight gain are more similar year-round, and could ac-
count for less seasonal variability. This hypothesis was
not supported by the finding that BMI SDS at the start
of the HV interval was unrelated to the number of day-
light hours (P = 0.28).
Our study was limited by the number of patients in
the NCGS database who were measured at every 3
monthly intervals. Patients measured at 6 monthly inter-
vals or longer were not included. Also, we do not have
IGF-1 levels to correlate with 3 monthly HV intervals.
25-hydroxyvitamin D levels, a reflection of nutrition and
ultraviolet light exposure, were also not assessed.Conclusion
In summary, there is seasonal variation in growth rate in
children with IGHD during rhGH therapy that is asso-
ciated with number of daylight hours and is greatest in
the first year of therapy. The effect is modest and, except
in extreme latitudes, is unlikely to interfere with short-
term assessment of efficacy of a trial of rhGH. This ob-
servation confirms that rate of growth in children is not
constant during the calendar year and underscores the
need to measure HV over a 12-month period for an ac-
curate assessment.
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